Stockreport

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets [Yahoo! Finance]

Nuvectis Pharma, Inc.  (NVCT) 
PDF Report highlights Nuvectis' potential to generate hundreds of millions of dollars in revenue and notes upcoming phase 1a clinical data as a potential catalyst NEW YORK [Read more]